16:09:40 EDT Sat 27 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:INO from 2023-04-27 to 2024-04-26 - 30 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-15 18:39U:INONews ReleaseINOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
2024-03-26 18:28U:INONews ReleaseINOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
2024-03-06 16:05U:INONews ReleaseINOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
2024-03-06 07:00U:INONews ReleaseGeneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting
2024-02-21 08:00U:INONews ReleaseINOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024
2024-02-07 11:46U:INONews ReleaseINOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2024-02-02 08:00U:INONews ReleaseINOVIO Reports Inducement Grant Under Inducement Plan
2024-01-23 08:00U:INONews ReleaseINOVIO Announces Effective Date of 1-for-12 Reverse Stock Split
2024-01-22 08:00U:INONews ReleaseINOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader
2024-01-04 08:00U:INONews ReleaseINOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI ¢ „ ¢ (toripalimab-tpzi)
2024-01-03 08:00U:INONews ReleaseINOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program
2023-11-09 16:05U:INONews ReleaseINOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights
2023-11-01 08:00U:INONews ReleaseINOVIO Reports Inducement Grants Under Inducement Plan
2023-10-26 08:00U:INONews ReleaseINOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023
2023-10-10 08:00U:INONews ReleaseINOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program
2023-09-27 19:39U:INONews ReleaseGeneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million
2023-09-07 08:00U:INONews ReleaseINOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
2023-08-29 08:00U:INONews ReleaseINOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-09 16:05U:INONews ReleaseINOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update
2023-08-04 08:00U:INONews ReleaseINOVIO Reports Inducement Grants Under Inducement Plan
2023-07-26 09:32U:INONews ReleaseINOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023
2023-06-23 16:10U:INONews ReleaseINOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
2023-06-01 08:00U:INONews ReleaseINOVIO Reports Inducement Grants Under Inducement Plan
2023-05-25 08:00U:INONews ReleaseINOVIO to Present at the 2023 Jefferies Healthcare Conference
2023-05-23 16:13U:INONews ReleaseINOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
2023-05-10 16:05U:INONews ReleaseINOVIO Reports First Quarter 2023 Financial Results and Operational Highlights
2023-05-08 08:00U:INONews ReleaseNew Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023
2023-05-05 08:00U:INONews ReleaseINOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference
2023-04-28 08:00U:INONews ReleaseINOVIO to Report First Quarter 2023 Financial Results on May 10, 2023
2023-04-27 08:00U:INONews ReleaseINOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023